How is Muenke syndrome inherited?

Muenke syndrome follows an autosomal dominant inheritance pattern. This means inheriting just one copy of the altered gene from either parent can cause the condition.

How rare is Muenke syndrome?

Muenke syndrome is classified as not well established. The estimated prevalence is approximately Unknown. Because rare disease data can be limited, actual numbers may differ from published estimates.

How is Muenke syndrome diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for Muenke syndrome?

Information about treatment is currently limited for this condition.

What complications can arise from Muenke syndrome?

Muenke syndrome can lead to several complications due to the early fusion of skull bones. These may include increased pressure inside the skull, which can affect brain development. Additionally, hearing loss and eye alignment issues can also be complications that require ongoing management.

How does Muenke syndrome affect daily life for individuals?

Daily life for individuals with Muenke syndrome can vary widely. Some may experience challenges like hearing loss or developmental delays, which can impact communication and learning. Regular check-ups with specialists can help manage these issues and support the individual's needs.

What is the life expectancy for someone with Muenke syndrome?

Currently, there is limited information about the life expectancy of individuals with Muenke syndrome. However, many people with this condition can lead fulfilling lives with appropriate medical care and support. Regular monitoring and treatment can help address any health concerns that arise.

What specialists should be involved in the care of someone with Muenke syndrome?

Individuals with Muenke syndrome may benefit from a team of specialists. This can include a craniofacial surgeon for any surgical needs, an audiologist for hearing assessments, and a developmental pediatrician for monitoring growth and development. Working with a team ensures comprehensive care tailored to the individual's needs.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Muenke syndrome - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Muenke syndrome

MONDO:0011274

Also known as:FGFR3-related craniosynostosisMNKESMuenke nonsyndromic coronal craniosynostosis

Find Clinical TrialsTrials

Overview

Muenke syndrome is a syndromic craniosynostosis with significant phenotypic variability, usually characterized by coronal synostosis, midfacial retrusion, strabismus, hearing loss and developmental delay.

GeneticsAutosomal dominant · FGFR3 (chr 4)

Clinical Trials1 registered · 1 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include common findings: Strabismus, Hearing loss (hearing impairment), Coronal craniosynostosis, and Thimble-shaped middle phalanges of hand and others; and sometimes findings: Brachydactyly, Seizure, Clinodactyly, and Macrocephaly and others. 35 total HPO annotations.

Organ System	Phenotype Count	Example Features
Arms and legs	5	Short middle phalanx of toe, Thimble-shaped middle phalanges of hand, Cone-shaped epiphyses of the phalanges of the hand

Genetic Landscape

Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.

FGFR3 encodes fibroblast growth factor receptor 3 (806 aa). Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Highest expression in Skin Not Sun Exposed Suprapubic (364.5 TPM) and Skin Sun Exposed Lower leg (356.5 TPM).

Muenke syndrome is caused by mutations in the FGFR3 gene on chromosome 4.

FGFR3 is classified as a druggable target (Cell Surface, Clinically Actionable, Drug Resistance, Druggable Genome, Kinase, and Tyrosine Kinase categories) with score 1.6.

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

Muenke syndrome should be suspected in individuals with the following clinical, radiographic, and family history findings. The phenotype is variable and ranges from no detectable clinical manifestations to the presence of craniosynostosis along with other classic features.

Clinical features

Source: GeneReviews — "Muenke Syndrome"

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for Muenke syndrome. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Muenke syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with Muenke Syndrome

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

Protocol-driven approaches to surveillance currently in use include those of and . This ideally involves multidisciplinary care by specialists in relevant fields . Table 6. Recommended Surveillance for Individuals with Muenke Syndrome

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

1 clinical trial registered, 1 recruiting. Interventions under study include gene therapy. Research is primarily sponsored by academic and government institutions.

12 publications have been identified in PubMed for Muenke syndrome. Research spans Case Report / Case Series (33%), Basic Science / Preclinical (25%), and Other (17%).

Research Type	Count	% of Total
Patient case studies	4	33%

Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 5:32 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:602849

Orphanet

European rare disease database

Orphanet:53271

GARD

Genetic and Rare Diseases Info Center

GARD:7097

Questions for Your Care Team

→Are any of the 1 active clinical trial a good fit for my situation?
→Should I pursue genetic testing for FGFR3, and what would the results mean for my family?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about Muenke syndrome

Muenke syndrome is a type of craniosynostosis where the bones in the skull fuse sooner than usual. This early fusion typically affects the coronal suture, which can change the shape of the skull and face. People with Muenke syndrome often show a wide range of characteristics. Common features include a midface that appears set back (midfacial retrusion), eye alignment issues (strabismus), hearing loss, and developmental delays. The variability in how the syndrome presents means that each person’s experience can be different.

Common signs in people with Muenke syndrome include the early fusion of the coronal suture, which can alter the shape of the skull. Additional features may include midfacial retrusion, strabismus (misaligned eyes), hearing loss, and developmental delays.

Muenke syndrome is associated with changes in the FGFR3 gene. These genetic changes can lead to the early fusion of skull bones, which is a hallmark of this form of syndromic craniosynostosis. Associated genes include FGFR3.

← Back to All Diseases

GeneReviews

Clinical Guidance

Muenke syndrome is characterized by coronal synostosis, and occasionally synostosis of other sutures, abnormal skull shape in those with synostosis, characteristic facies, hearing loss, and strabismus. Additional features can include developmental delay, intellectual disability, epilepsy, intracranial anomalies, brachydactyly, broad thumbs and great toes, and/or clinodactyly. Penetrance is incomplete, and phenotypic variability is considerable even within the same family. Some individuals have minor clinical signs such as macrocephaly and subtle facial findings without craniosynostosis; some have only radiographic features . To date, more than 100 individuals have been identified with a pathogenic variant in FGFR3 . The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Muenke Syndrome: Frequency of Select Features

Feature	% of Personsw/Feature	Comment
Coronal synostosis	~85%	—
Synostosis of other sutures	~3	—
Hearing loss	70%	—
Developmental delay	60%	—
Intellectual disability	40%	—
Behavioral issues	~50%	—
Ocular anomalies	60%	Strabismus in 39%-66%
Limb findings	~50%	Craniosynostosis and craniofacial features. Coronal synostosis may be bilateral (~2/3 of affected individuals) or unilateral (~1/3 of affected individuals) .

Source: GeneReviews — "Muenke Syndrome"

Kisho

Muenke syndrome

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Clinical Guidance

Explore clinical features

Penetrance

Penetrance is reduced. Some individuals heterozygous for the FGFR3

Differential Diagnosis

FGFR3

Therapies Under Investigation

Clinical Trials

Recent Publications

Muenke syndrome

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Muenke syndrome?

What are the symptoms of Muenke syndrome?

What causes Muenke syndrome?

How is Muenke syndrome inherited?

How rare is Muenke syndrome?

How is Muenke syndrome diagnosed?

Are there treatments for Muenke syndrome?

What complications can arise from Muenke syndrome?

How does Muenke syndrome affect daily life for individuals?

What is the life expectancy for someone with Muenke syndrome?

What specialists should be involved in the care of someone with Muenke syndrome?

Clinical Guidance

Explore clinical features

Penetrance

Penetrance is reduced. Some individuals heterozygous for the FGFR3

Differential Diagnosis

FGFR3

Therapies Under Investigation

Clinical Trials

Recent Publications